Abstract |
Seventeen patients with residual or recurrent colorectal carcinoma were given a new synthetic immunomodulator [3,6-bis(2-piperidinoethoxy) acridine trihydrochloride CL246738) as part of a phase I clinical trial. No patients had undergone previous immunotherapy or chemotherapy. Detailed immunological studies including interferon levels, interleukin 2 levels, natural killer cell function, mitogen responses of lymphocytes, immunoglobulin levels and lymphocyte subpopulation levels were analysed in the patients who received this drug in an attempt to find out whether there was any biological activity identifiable in humans. None of the subjects showed any significant increases in post treatment values of the immunological parameters studied. Toxic effects of the drug at high doses included nausea, diarrhoea and decreased levels of consciousness. In conclusion, no immunological effects were identified following the administration of CL 246738 in human subjects with recurrent or residual colorectal cancer.
|
Authors | T W Lennard, A L Harris, J Hales, A Dickinson, R Wolstencroft, P Halcrow, B K Shenton, M McDonald, G F Lawrence, R M Taylor |
Journal | European journal of cancer & clinical oncology
(Eur J Cancer Clin Oncol)
Vol. 25
Issue 11
Pg. 1571-6
(Nov 1989)
ISSN: 0277-5379 [Print] England |
PMID | 2591449
(Publication Type: Journal Article)
|
Chemical References |
- Acridines
- Adjuvants, Immunologic
- Antineoplastic Agents
- 3,6-bis(2-piperidinoethoxy)acridine trihydrochloride
|
Topics |
- Acridines
(adverse effects, therapeutic use)
- Adenocarcinoma
(drug therapy)
- Adjuvants, Immunologic
(adverse effects, therapeutic use)
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Colorectal Neoplasms
(drug therapy)
- Drug Evaluation
- Female
- Humans
- Male
- Middle Aged
|